The February 20, 2017, article by Choueiri, et al, entitled “Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial” (J Clin Oncol 35:591-597), was published with errors. The investigator team upon detailed review of the study charts found errors or significant changes from the original report.

中文翻译：

---

勘误表。

2017年2月20日，Choueiri等人发表的文章，标题为“卡波赞尼与舒尼替尼作为不良或中度转移性肾细胞癌患者的初步靶向治疗：Alliance A031203 CABOSUN试验”（J Clin Oncol 35：591-597 ），发布时出现错误。研究人员在对研究图表进行详细审查后发现与原始报告存在错误或重大变化。